At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Mesna, and 6 other interventions for Lymphoma. Completed, enrolled 55 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
Study Details
Timeline
Interventions
Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.